- Home
- TRIP vs GLUE Comparison
TRIP vs GLUE Comparison
Compare TRIP & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRIP | GLUE |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TRIP | GLUE |
|---|---|---|
| Price | $10.87 | $20.09 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 3 |
| Target Price | $14.58 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 3.7M | 998.0K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 675.00 | N/A |
| EPS | ★ 0.31 | N/A |
| Revenue | ★ $1,556,000,000.00 | $123,672,000.00 |
| Revenue This Year | $3.33 | N/A |
| Revenue Next Year | $5.12 | $2.45 |
| P/E Ratio | ★ $35.42 | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $9.01 | $3.76 |
| 52 Week High | $20.16 | $25.77 |
Technical Indicators
Market Signals| Indicator | TRIP | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 49.71 | 64.47 |
| Support Level | $9.36 | $17.36 |
| Resistance Level | $11.08 | $20.24 |
| Average True Range (ATR) | 0.50 | 1.04 |
| MACD | 0.00 | 0.41 |
| Stochastic Oscillator | 17.62 | 70.17 |
Price Performance
Historical ComparisonAbout TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2025, 42% of revenue came from the company's core Hotel and Other segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of revenue in 2025, and TheFork, its dining brand, represented 12% of sales.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).